The Central Drugs Standard Control Organization (CDSCO) on August 11, 2023, issued a notification regarding the alert on Suspected Falsified Versions of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1-RA) Products.
The following has been stated: -
•The World Health Organization (WHO) has informed about a safety threat that has been identified with falsified versions of Glucagon-like Peptide 1 Receptor Agonist (GLP-1-RA) products.
•The WHO has received several reports of falsified GLP-1 receptor agonists and it was informed that since late 2022, global demand for GLP-1-RA products has risen, with reported shortages adversely impacting people living with Diabetes Type II.
•Glucagon-like peptide 1 receptor agonists (GLP-1-RA) are a class of pharmaceuticals indicated to manage Diabetes Type II, which are also sought for weight loss. They are marketed globally under a variety of brands.
•The Doctors and Healthcare professionals should carefully prescribe and suggest an alternative if the need arises. Further, educate their patients for reporting any ADRs with the usage of procured medical products like GLP-1-RA products.
The detailed notification is given in the document attached below.
[Notification No. ED/Misc./212/2023]
